Clinical Edge Journal Scan

Maternal psychological distress in prenatal and postnatal periods increases risk for atopic dermatitis in children


 

Key clinical point: Children born to mothers who had a cumulative exposure to psychological distress in the prenatal and postnatal periods were at an increased risk of developing atopic dermatitis (AD) at 1-2 years of age.

Major finding: Maternal psychological distress vs. no psychological distress in both prenatal and postnatal periods (adjusted relative risk [RR] 1.34; 95% CI 1.20-1.47) and only in the postnatal period (adjusted RR 1.23; 95% CI 1.07-1.39) was significantly associated with an increased risk of developing AD in children at 1-2 years of age.

Study details: This study analyzed maternal psychological distress during early pregnancy and 1 year after delivery in 8377 mother-child pairs, wherein the child had not developed AD by the age of 1 year.

Disclosures: This study was supported by the Ministry of Education, Culture, Sports, Science, and Technology, Japan. K Murakami declared being an editorial board member of BMC Public Health.

Source: Kawaguchi C et al. Cumulative exposure to maternal psychological distress in the prenatal and postnatal periods and atopic dermatitis in children: Findings from the TMM BirThree Cohort Study. BMC Pregnancy Childbirth. 2022;22:242 (Mar 24). Doi: 10.1186/s12884-022-04556-8

Recommended Reading

Global registry tracks COVID-19 outcomes in atopic dermatitis patients
MDedge Dermatology
Clinical Edge Journal Scan Commentary: Atopic Dermatitis April 2022
MDedge Dermatology
Review of Ethnoracial Representation in Clinical Trials (Phases 1 Through 4) of Atopic Dermatitis Therapies
MDedge Dermatology
Probiotic LGG doesn’t lessen eczema, asthma, or rhinitis risk by age 7
MDedge Dermatology
Cupping in dermatology
MDedge Dermatology
Meta-analysis presents relative effect estimates for systemic immunomodulatory treatments for atopic dermatitis
MDedge Dermatology
Effect of dupilumab on SARS-CoV-2 antibody response in atopic dermatitis
MDedge Dermatology
Meta-analysis evaluates efficacy and safety of oral and topical JAKi in atopic dermatitis
MDedge Dermatology
BNT162b2 SARS-CoV-2 vaccination highly recommended for patients with atopic dermatitis
MDedge Dermatology
Patients with chronic rhinosinusitis are at risk for subsequent atopic dermatitis
MDedge Dermatology